newsfilter
← Latest News
GlobeNewswire·

Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications

-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults (administration post-primary